T cell-mediated immune responses in melanoma: Implications for immunotherapy

Critical Reviews in Oncology/Hematology

Volumn 43, Issue 1, 2002, Pages 1-11

  Wang, Rong Fu ^a   Johnston, Samuel F ^c   Zeng, Gang ^a,b   Ying, Han ^d  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antigen presentation; Cancer vaccines; CD4+ T cells; Cytotoxic T lymphocytes; Immunization; Immunotherapy MHC class II; Tumor antigens

Indexed keywords

ANTIGEN; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUTANT PROTEIN; PEPTIDE; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MELANOMA; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; MUTATION; OPEN READING FRAME; PROTEIN DETERMINATION; REVIEW; T LYMPHOCYTE; TESTIS; TISSUE SPECIFICITY; VIRUS RECOMBINANT;

ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY; MELANOMA; T-LYMPHOCYTES;

EID: 0036289885     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00186-X     Document Type: Review

References (138)

1. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report
2. The immunotherapy and gene therapy of cancer
3. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt1+2- lymphocytes
4. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
5. CD4+ helper T cells are required for resistance to a highly metastatic murine tumor
6. Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers
7. The central role of CD4(+) T Cells in the antitumor immune response
8. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
9. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
10. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
11. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection
12. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
13. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
14. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
15. Gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'Self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
16. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
17. Recognition of an antigenic peptide derived from TRP-2 by cytotoxic T lymphocytes in the context of HLA-A31 and -A33
18. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs
19. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules
20. Shared epitopes for HLA-A3 -restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100
21. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development
22. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles
23. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients
24. Identification of a new HLA-A(*)0201∼restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen
25. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3
26. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2
27. Sequential chemoimmunotherapy in the treatment of metastatic melanoma
28. Vitiligo in patients with melanoma: Normal tissue antigens can be targeted for cancer immunotherapy
29. Tumor immunity and autoimmunity induced by immunization with homologous DNA
30. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
31. Coupling and uncoupling of tumor immunity and autoimmunity
32. Generation of cytotoxic T cell responses with synthetic melanoma-associated peptides in vivo: Implication for tumor vaccines with melanoma-associated antigens
33. Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patients with metastatic melanoma
34. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
35. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma
36. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
37. Increased vaccine-specific T cell frequency after peptide based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
38. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
39. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
40. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
41. A gene encoding an antigen recognized by cytolytiv T lymphocytes on a human melanoma
42. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
43. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
44. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
45. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
46. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
47. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
48. NY-ESO-1 may be a potential target for lung cancer immunotherapy
49. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele
50. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
51. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules
52. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
53. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
54. Ny-eso-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade
55. Immunity to oncogenic proteins
56. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p2lras peptide presented by HLA-A*0201
57. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
58. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes
59. P53, a potential target for tumor-directed T cells
60. Targeting p53 as a general tumor antigen
61. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
62. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
63. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
64. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma
65. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC
66. Stabilization of beta-catenin by genetic defects in melanoma cell lines
67. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
68. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen
69. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1
70. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ
71. LAGE-1, a new gene with tumor specificity
72. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma
73. An alternative open reading frame of the human macrophage colony- stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes
74. An alternative translational reading frame encodes an immunodominant retroviral CTL determinant expressed by an immunodeficiency-causing retrovirus
75. Non-traditionally derived CTL epitopes: Exceptions that prove the rules?
76. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription
77. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene
78. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes
79. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
80. Tumor immunotherapy: The tumor cell as an antigen-presenting cell
81. The role of CD4(+) T cell responses in antitumor immunity
82. CD4 T Cells and their role in antitumor immune responses
83. CD4+ T cells orchestrate both amplification and deletion of CD8+ T cells
84. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
85. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase
86. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient
87. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recoginzed by melanoma-reactive CD4(+) T cells
88. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells
89. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
90. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes
91. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
92. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes
93. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells
94. Identification of NY-ESO-l epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
95. CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA-DP4 allele: Association with NY-ESO-1 antibody production
96. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules
97. Identification of a novel MHC class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells
98. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells
99. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen
100. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
101. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides
102. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues
103. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
104. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL
105. Dendritic cells and the control of immunity
106. Dendritic cell vaccines for cancer immunotherapy
107. The dendritic cell and human cancer vaccines
108. Gene-modified dendritic cells for use in tumor vaccines
109. Genetic immunization is a simple method for eliciting an immune response
110. Heterologous protection against influenza by injection of DNA encoding a viral protein
111. The new vaccines: Building viruses that elicit antitumor immunity
112. DNA vaccines: Immunology, application, and optimization
113. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
114. The role of CpG motifs in innate immunity
115. Semiiki Forest virus-based DNA expression vector: Transient protein production followed by cell death
116. Cancer therapy using a self-replicating RNA vaccine
117. Costimulatory wars: The tumor menace
118. Costimulation of T cells for tumor immunity
119. Enhancement of antitumor immunity by CTLA-4 blockade
120. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
121. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism
122. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
123. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy
124. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
125. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
126. T-cell co-stimulation through B7RP-1 and ICOS
127. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
128. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha
129. Help for cytotoxicT-cell responses is mediated by CD40 signalling
130. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
131. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
132. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
133. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
134. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40
135. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
136. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor
137. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma